Pharmaceutical outsourcing sector on track for a
record-breaking year
M&A activity propels pharma outsourcing deals to $17bn
LONDON, December 11, 2015
A drastic increase in mergers and acquisitions (M&A) activity has propelled the value of pharmaceutical outsourcing deals to nearly $17.6 billion through October, from $9.9 billion last year.
It has put the sector on track for a record-breaking year, according to an analyst with research and consulting firm GlobalData.
In an article for Arena International’s Clinical Trial Year Book 2016, Adam Dion, GlobalData’s senior healthcare industry analyst, said that while the pharmaceutical outsourcing services sector has seen a sharp rise in M&A activity in recent years, the value of deals has more than doubled over the past year, from $5.5 billion in 2014, to $12 billion by October.
“This year has seen a number of high-valued transactions, including LabCorp’s $6.1 billion purchase of Covance, and WuXi being sold for $3.3 billion to a Chinese private equity group,” he said.
“Contract manufacturers have also been busy in 2015. Siegfried Holding AG, an API maker based in Switzerland, bought BASF’s pharmaceutical supply business, and Lannett acquired Kremers Urban Pharmaceuticals, a specialty generic drug maker and subsidiary of UCB, for $1.2 billion.”
LabCorp acquired clinical trial contractor Covance under a cash and stock deal valued at approximately $6.1 billion.
The combined business will now have pro forma revenue of nearly $8.4 billion, vaulting it ahead of its closest rival, Quest Diagnostics, and establishing a new leader in the medical testing space.
“LabCorp’s intentions seem pretty clear – it wants a larger piece of the Contract Research Organization (CRO) market,” said Dion.
“The CRO sector has enjoyed impressive growth over the past few years, as plummeting sales from the loss of exclusivity branded drugs, the high cost of pharmaceutical research and development, and the globalization of clinical trials, have led to a surge in demand for outsourced clinical trial work,” he said.
“GlobalData expects that Covance will act as a separate entity under the LabCorp moniker, in which LabCorp can leverage Covance’s leadership in clinical trials monitoring, patient and sponsor recruitment, and study site selection through its proprietary Xcellerate technology platform.” - TradeArabia News Service
